Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overcoming adaptive therapy resistance in AML by targeting immune response pathways
Katelyn Melgar, Morgan M. Walker, LaQuita M. Jones, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 508
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification
Bowen Li, Jingwen Jiang, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100720-100720
Closed Access | Times Cited: 141
Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer
Kaiyang Zhang, Erdoğan Pekcan Erkan, Sanaz Jamalzadeh, et al.
Science Advances (2022) Vol. 8, Iss. 8
Open Access | Times Cited: 117
Visualization nanozyme based on tumor microenvironment “unlocking” for intensive combination therapy of breast cancer
Zhiyi Wang, Ziyuan Li, Zhaoli Sun, et al.
Science Advances (2020) Vol. 6, Iss. 48
Open Access | Times Cited: 131
Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis
Masayuki Yamashita, Paul V. Dellorusso, Oakley C. Olson, et al.
Nature reviews. Cancer (2020) Vol. 20, Iss. 7, pp. 365-382
Open Access | Times Cited: 128
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance
Sunil K. Joshi, Tamilla Nechiporuk, Daniel Bottomly, et al.
Cancer Cell (2021) Vol. 39, Iss. 7, pp. 999-1014.e8
Open Access | Times Cited: 102
Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia
Timothy M. Chlon, Emily Stepanchick, Courtney E. Hershberger, et al.
Cell stem cell (2021) Vol. 28, Iss. 11, pp. 1966-1981.e6
Open Access | Times Cited: 68
Glycyrrhetinic acid nanoparticles combined with ferrotherapy for improved cancer immunotherapy
Qing Li, Rui Su, Xin Bao, et al.
Acta Biomaterialia (2022) Vol. 144, pp. 109-120
Closed Access | Times Cited: 66
FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance
Zhijie Wang, Jiongheng Cai, Jie Cheng, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 6, pp. 2878-2900
Closed Access | Times Cited: 64
IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies
Joshua Bennett, Daniel T. Starczynowski
Current Opinion in Hematology (2021) Vol. 29, Iss. 1, pp. 8-19
Open Access | Times Cited: 62
The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation
Anna Yeaton, Geraldine Cayanan, Sanam Loghavi, et al.
Cancer Discovery (2022) Vol. 12, Iss. 10, pp. 2392-2413
Open Access | Times Cited: 51
Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy
Martina Ruglioni, Stefania Crucitta, Giovanna Irene Luculli, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 201, pp. 104424-104424
Open Access | Times Cited: 12
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia
Melat T. Gebru, Hong‐Gang Wang
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 61
Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets
Tiansu Wang, Allison R. Pine, Andriana G. Kotini, et al.
Cell stem cell (2021) Vol. 28, Iss. 6, pp. 1074-1089.e7
Open Access | Times Cited: 48
Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition
Wei Wei, Mitchell J. Geer, Xinyi Guo, et al.
The Journal of Experimental Medicine (2023) Vol. 220, Iss. 5
Open Access | Times Cited: 21
The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases
Yi‐Ru Bai, Weiguang Yang, Xuehui Hou, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115606-115606
Closed Access | Times Cited: 20
Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML
Joshua Bennett, Chiharu Ishikawa, Puneet Agarwal, et al.
Blood (2023) Vol. 142, Iss. 11, pp. 989-1007
Open Access | Times Cited: 18
Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation
Juan José Rodríguez‐Sevilla, Vera Ademà, Guillermo Garcia‐Manero, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 2, pp. 100940-100940
Open Access | Times Cited: 17
FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia
Pamela J. Sung, Murugan Selvam, Simone S. Riedel, et al.
Leukemia (2024) Vol. 38, Iss. 2, pp. 291-301
Open Access | Times Cited: 8
Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1
Daniel Coleman, Peter Keane, Paulynn Suyin Chin, et al.
iScience (2024) Vol. 27, Iss. 4, pp. 109576-109576
Open Access | Times Cited: 7
Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Rucha V. Modak, Katia G. de Oliveira Rebola, John McClatchy, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2245-2259
Open Access | Times Cited: 6
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia
Laura Barreyro, Avery Sampson, Chiharu Ishikawa, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 635
Closed Access | Times Cited: 24
Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer
Guillermo Garcia‐Manero, Uwe Platzbecker, Kian‐Huat Lim, et al.
Frontiers in Hematology (2024) Vol. 3
Open Access | Times Cited: 5
Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia
Luyao Long, Yehuda G. Assaraf, Zi‐Ning Lei, et al.
Drug Resistance Updates (2020) Vol. 52, pp. 100703-100703
Closed Access | Times Cited: 37
Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
Melisa Tecik, Aysun Adan
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 1449-1478
Open Access | Times Cited: 22
Inhibition of NLRP3 enhances pro-apoptotic effects of FLT3 inhibition in AML
Helene Sieberer, Michela Luciano, Diana Amend, et al.
Cell Communication and Signaling (2025) Vol. 23, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top